In BRAF wild-type (BRAFWT) melanoma cells, the MAPK kinase pathway is activated by vemurafenib (and the analogous PLX4720) leading to upregulation of MEK and ERK and enhanced proliferation [68, 69]. Here, MAP2K7 is linked to melanoma.